---
input_text: Muscle-directed AAV gene therapy rescues the maple syrup urine disease
  phenotype in a mouse model. Maple syrup urine disease (MSUD) is a rare, inherited
  metabolic disorder characterized by a dysfunctional mitochondrial enzyme complex,
  branched-chain alpha-keto acid dehydrogenase (BCKDH), which catabolizes branched-chain
  amino acids (BCAAs). Without functional BCKDH, BCAAs and their neurotoxic alpha-keto
  intermediates can accumulate in the blood and tissues. MSUD is currently incurable
  and treatment is limited to dietary restriction or liver transplantation, meaning
  there is a great need to develop new treatments for MSUD. We evaluated potential
  gene therapy applications for MSUD in the intermediate MSUD (iMSUD) mouse model,
  which harbors a mutation in the dihydrolipoamide branched-chain transacylase E2
  (DBT) subunit of BCKDH. Systemic delivery of an adeno-associated virus (AAV) vector
  expressing DBT under control of the liver-specific TBG promoter to the liver did
  not sufficiently ameliorate all aspects of the disease phenotype. These findings
  necessitated an alternative therapeutic strategy. Muscle makes a larger contribution
  to BCAA metabolism than liver in humans, but a muscle-specific approach involving
  a muscle-specific promoter for DBT expression delivered via intramuscular (IM) administration
  only partially rescued the MSUD phenotype in mice. Combining the muscle-tropic AAV9
  capsid with the ubiquitous CB7 promoter via IM or IV injection, however, substantially
  increased survival across all assessed doses. Additionally, near-normal serum BCAA
  levels were achieved and maintained in the mid- and high-dose cohorts throughout
  the study; this approach also protected these mice from a lethal high-protein diet
  challenge. Therefore, administration of a gene therapy vector that expresses in
  both muscle and liver may represent a viable approach to treating patients with
  MSUD.
raw_completion_output: |-
  primary_disease: Muscle syrup urine disease (MSUD)

  medical_actions: Dietary restriction; Liver transplantation; Gene therapy applications; Systemic delivery of an adeno-associated virus (AAV) vector; Intramuscular (IM) administration; Intravenous (IV) injection

  symptoms: Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto intermediates in the blood and tissues

  chemicals: Adeno-associated virus (AAV) vector

  action_annotation_relationships: Dietary restriction PREVENTS Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto intermediates IN Muscle syrup urine disease (MSUD); Liver transplantation PREVENTS Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto intermediates IN Muscle syrup urine disease (MSUD); Gene therapy applications (with Adeno-associated virus (AAV) vector) TREATS Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto intermediates IN Muscle syrup urine disease (MSUD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Gene therapy applications (with Adeno-associated virus (AAV) vector) TREATS Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto intermediates IN Muscle syrup urine disease (MSUD)

  ===

extracted_object:
  primary_disease: MONDO:0009563
  medical_actions:
    - Dietary restriction
    - MAXO:0001175
    - Gene therapy applications
    - Systemic delivery of an adeno-associated virus (AAV) vector
    - Intramuscular (IM) administration
    - Intravenous (IV) injection
  symptoms:
    - Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic alpha-keto
      intermediates in the blood and tissues
  chemicals:
    - Adeno-associated virus (AAV) vector
  action_annotation_relationships:
    - subject: Dietary restriction
      predicate: PREVENTS
      object: Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic
        alpha-keto intermediates
      qualifier: MONDO:0009563
      subject_extension: Dietary restriction
    - subject: MAXO:0001175
      predicate: PREVENTS
      object: Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic
        alpha-keto intermediates
      qualifier: MONDO:0009563
    - subject: Gene therapy applications
      predicate: TREATS
      object: Accumulation of branched-chain amino acids (BCAAs) and their neurotoxic
        alpha-keto intermediates
      qualifier: MONDO:0009563
      subject_qualifier: with Adeno-associated virus (AAV) vector
      subject_extension: Adeno-associated virus (AAV) vector
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:21547
    label: N-acetylaspartate (NAA)
  - id: CHEBI:16919
    label: Creatine
  - id: HP:0006846
    label: acute encephalopathy
  - id: HP:0033667
    label: mental impairment (IQ <= 70)
  - id: HP:0001943
    label: Hypoglycemia
  - id: HP:0001257
    label: Spasticity
  - id: HP:0000988
    label: Rash
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0030005
    label: Capillary leak syndrome
  - id: CHEBI:176838
    label: Riboflavin (vitamin B2)
  - id: CHEBI:176841
    label: Biotin (vitamin B7)
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0010911
    label: Hyperleucinemia
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0000938
    label: osteopenia
  - id: CHEBI:28938
    label: ammonia
  - id: CHEBI:30860
    label: methylmalonic acid
  - id: CHEBI:15702
    label: Tissue plasminogen activator (tPA)
  - id: HP:0001699
    label: sudden death
  - id: MAXO:0000932
    label: Electroencephalography
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002586
    label: peritonitis
  - id: HP:0003774
    label: chronic renal failure
  - id: MONDO:0008723
    label: Very-long chain acyl-CoA dehydrogenase deficiency (VLCAD)
  - id: CHEBI:17453
    label: methylmalonate
  - id: MONDO:0002012
    label: Methylmalonic Acidemia
  - id: MONDO:0008815
    label: Argininosuccinic Aciduria (ASA)
  - id: MAXO:0000602
    label: Hemodialysis (HD)
  - id: HP:0002344
    label: Neurologic deterioration
  - id: MONDO:0007100
    label: Familial Amyloid Polyneuropathy
  - id: MONDO:0005439
    label: Familial Hypercholesterolemia
  - id: HP:0002181
    label: Brain swelling
  - id: HP:0034254
    label: Face of the Giant Panda Sign
  - id: MAXO:0000112
    label: Antioxidant therapies
  - id: HP:0025464
    label: Oxidative stress
  - id: MAXO:0000917
    label: Stenting
  - id: HP:0030242
    label: Portal vein thrombosis
  - id: CHEBI:28939
    label: N-acetylcysteine
  - id: CHEBI:16796
    label: Melatonin
  - id: CHEBI:51596
    label: 2',7'-dichlorofluorescein
  - id: CHEBI:566274
    label: Malondialdehyde
  - id: CHEBI:16856
    label: Reduced glutathione
  - id: HP:0007018
    label: attention deficits
